Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans Summer Cancer Meeting

Dr. Edgardo Santos' Interview with Pasquale W. Benedetto, MD

Dr. Benedetto underscored that maintaining dose intensity and following biomarkers are critical to preventing relapses in rare testicular cancer, recommending sperm banking before treatment and annual post-treatment follow-ups. He alsoreassured that most patients can preserve fertility and achieve normal lifespans with experienced, guideline-driven care.

Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans Summer Cancer Meeting
NOSCM

Dr. Edgardo Santos' Interview with Sanjiv Agarwala, MD, FASCO

Dr. Sanjeev Agarwalareviewed advances in melanoma therapy, highlighting promising phase II results combining RNA-based vaccines with pembrolizumab, which enhanced anti-tumor response without added toxicity. He noted that dual LAG-3/PD-1 blockade offersefficacy comparable to ipilimumab/nivolumab but with a more favorable safety profile and neoadjuvant ipilimumab for stage III melanoma, which may obviate the need for additional post-surgical treatments.

Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans Summer Cancer Meeting

NOSCM-071924 - Dr E.dgardo S. Santos with Dr Ahmed Zakari Interview

Drs. Santos and Zakari highlighted that tumor-informed ctDNA testing in oligometastatic colorectal cancer can detect minimal residual disease—helping identify patients unlikely to benefit from adjuvant chemotherapy—with repeat assays raising sensitivity to 80–85%. They also noted ASCO’s recent preference for fluorouracil in upper GI adenocarcinomas and underscored ctDNA’s prognostic value in the GALAXY trial.